Premium
Ten‐yr renal allograft survival of patients with antiphospholipid antibody syndrome
Author(s) -
Vaidya Smita
Publication year - 2012
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/j.1399-0012.2012.01625.x
Subject(s) - medicine , antiphospholipid syndrome , antibody , immunology
Background Long‐term allograft survival of antiphospholipid antibody syndrome ( APAS ) patients as well as patients who have antiphospholipid antibodies but no thrombotic complications remains largely unknown. This study evaluates long‐term allograft survival of APA as well as patients with APAS . Methods During the study period from J anuary 1, 1992 through M ay 31, 2009, 1625 patients with ESRD awaiting renal transplants were screened for APAS . Ninety‐four (5.8%) of these patients had circulating levels of anticardiolipin antibodies ( ACA ) and 39 of these patients had documented evidence of clotting disorders and were diagnosed with APAS . Twenty‐one patients with APAS received transplants on either low molecular weight ( LMW ) heparin or C oumadin as anticoagulation therapy. Of 94 patients with only ACA , 46 received renal transplants. Of the remaining 1492 patients, 1285 patients with no evidence of either ACA or APAS received renal transplants. Results Ten‐yr allograft survival of patients with APAS treated with C oumadin was similar to those treated with LMW heparin (18% vs. 20%, NS ). However, those allograft survivals were significantly lower than those patients positive for ACA (28%) alone ( ACA vs. LMW heparin or C oumadin p = 0.0001). Conclusion Despite anticoagulation therapies, patients with APAS have lower long‐term graft survival than those patients who have circulating ACA but no APAS .